CytomX Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for CytomX Therapeutics, Inc. (CTMX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CTMX insiders buying or selling?
In the last 12 months, CytomX Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 7 sales ($2.2M) — net selling of $2.2M. Since January 2018, Trabud has recorded 78 Form 4 filings for CTMX: 2 buys ($100.7K) and 76 sells ($11.0M).
Source: SEC EDGAR Form 4
What stands out
- No CytomX Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 7 reported open-market sales totaled $2.2M.
Key Statistics (January 2018 – Oct 16, 2026)
Total Form 4 filings
78
SEC EDGAR
Insider filers
13
Insider buys (2)
$100.7K
Insider sells (76)
$11.0M
Insider sentiment
Net sellingNet insider flow of $10.9M in net selling since January 2018, and $2.2M in net selling over the last 12 months.
Recent CTMX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Sean A. Mccarthy | CEO | Sale | 101.8K | $4.54 | $461.9K | SEC ↗ |
| Jun 17, 2026 | Christopher Ogden | Chief Financial Officer | Sale | 1.6K | $3.05 | $5.0K | SEC ↗ |
| Mar 19, 2026 | Yu-Waye Chu | Chief Medical Officer | Sale | 21.3K | $6.42 | $136.7K | SEC ↗ |
| Mar 19, 2026 | Sean A. Mccarthy | CEO | Sale | 119.0K | $6.42 | $764.1K | SEC ↗ |
| Mar 19, 2026 | Marcia Belvin | SVP, Chief Scientific Officer | Sale | 31.5K | $6.42 | $202.3K | SEC ↗ |
| Mar 19, 2026 | Christopher Ogden | Chief Financial Officer | Sale | 19.3K | $6.42 | $124.1K | SEC ↗ |
| Nov 10, 2025 | Sean A. Mccarthy | CEO | Sale | 101.8K | $4.54 | $461.9K | SEC ↗ |
| Jun 17, 2025 | Christopher Ogden | Chief Financial Officer | Sale | 12.3K | $2.72 | $33.4K | SEC ↗ |
| Jun 17, 2025 | Marcia Belvin | SVP, Chief Scientific Officer | Sale | 13.9K | $2.69 | $37.3K | SEC ↗ |
| Jun 17, 2025 | Sean A. Mccarthy | CEO | Sale | 55.5K | $2.69 | $149.3K | SEC ↗ |
| Mar 20, 2025 | Sean A. Mccarthy | CEO | Sale | 37.7K | $0.60 | $22.6K | SEC ↗ |
| Mar 20, 2025 | Christopher Ogden | Chief Financial Officer | Sale | 8.6K | $0.60 | $5.1K | SEC ↗ |
| Mar 20, 2025 | Yu-Waye Chu | Chief Medical Officer | Sale | 4.0K | $0.60 | $2.4K | SEC ↗ |
| Mar 20, 2025 | Lloyd A Rowland | General Counsel | Sale | 10.2K | $0.60 | $6.1K | SEC ↗ |
| Mar 20, 2025 | Marcia Belvin | SVP, Chief Scientific Officer | Sale | 19.5K | $0.60 | $11.7K | SEC ↗ |
| Aug 22, 2024 | Jeffrey B Landau | Chief Business Officer | Sale | 4.2K | $1.23 | $5.1K | SEC ↗ |
| Aug 22, 2024 | Marcia Belvin | SVP, Chief Scientific Officer | Sale | 4.2K | $1.23 | $5.1K | SEC ↗ |
| Aug 22, 2024 | Lloyd A Rowland | General Counsel | Sale | 4.2K | $1.23 | $5.1K | SEC ↗ |
| Aug 22, 2024 | Christopher Ogden | Chief Financial Officer | Sale | 2.0K | $1.23 | $2.4K | SEC ↗ |
| Aug 22, 2024 | Sean A. Mccarthy | CEO | Sale | 13.9K | $1.23 | $17.1K | SEC ↗ |
| Mar 21, 2024 | Lloyd A Rowland | General Counsel | Sale | 5.3K | $2.09 | $11.0K | SEC ↗ |
| Mar 21, 2024 | Sean A. Mccarthy | CEO | Sale | 20.2K | $2.09 | $42.2K | SEC ↗ |
| Mar 21, 2024 | Christopher Ogden | SVP, Finance and Accounting | Sale | 3.0K | $2.09 | $6.2K | SEC ↗ |
| Mar 21, 2024 | Marcia Belvin | SVP, Chief Scientific Officer | Sale | 12.8K | $2.09 | $26.7K | SEC ↗ |
| Mar 21, 2024 | Jeffrey B Landau | Chief Business Officer | Sale | 6.6K | $2.09 | $13.7K | SEC ↗ |
Showing the 25 most recent of 78 Form 4 filings for CytomX Therapeutics, Inc..
Most active CTMX insiders
- Sean A. Mccarthy23 filings
- Debanjan Ray12 filings
- Christopher Ogden8 filings
- Lloyd A Rowland8 filings
- Marcia Belvin7 filings
Ask anything about CTMX insider activity
Use Trabud's AI agent to query CytomX Therapeutics, Inc.'s Form 4 history in plain English — "Show me CTMX CEO purchases this year" or compare it against any other ticker.
Open the AI agentCTMX insider trading FAQ
Are CytomX Therapeutics, Inc. insiders buying or selling?
In the last 12 months, CytomX Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 7 sales ($2.2M) — net selling of $2.2M. Since January 2018, Trabud has recorded 78 Form 4 filings for CTMX: 2 buys ($100.7K) and 76 sells ($11.0M). Over the full record that is net selling of $10.9M.
How many insiders trade CTMX stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for CytomX Therapeutics, Inc.. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get CTMX insider trading data?
All CTMX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.